The AMOTL2 (Angiomotin-like protein 2) antibody is a research tool designed to detect AMOTL2. a member of the angiomotin protein family involved in cell polarity, migration, and angiogenesis. AMOTL2 contains conserved coiled-coil and PDZ-binding domains, enabling interactions with cytoskeletal components and signaling molecules like YAP/TAZ in the Hippo pathway. It regulates cell-cell adhesion, actin dynamics, and organ size control by modulating Hippo-mediated transcriptional activity. Studies implicate AMOTL2 in embryonic development, tissue homeostasis, and cancer progression, though its role remains debated—some reports suggest tumor-suppressive functions, while others link its overexpression to metastasis.
The antibody is typically generated in rabbits or mice using immunogenic peptides or recombinant protein fragments. It is validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence to study AMOTL2 expression, localization, and post-translational modifications (e.g., phosphorylation). Specificity is confirmed via knockout controls or siRNA knockdown. Researchers use AMOTL2 antibodies to explore its dual roles in physiological processes and pathologies, particularly in cancers (breast, prostate, glioblastoma) and vascular disorders. Commercial variants may differ in clonality, epitope recognition, or conjugation tags. Optimal performance depends on protocol standardization due to potential cross-reactivity with homologous family members (AMOT, AMOTL1).